<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 167 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page166.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=167">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 167 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 167</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=167"><img src="../thumb/167.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>136 / 2020-04                                                        Blood and Haemopoeitic - 8.1

              THE NOAC* YOU AND YOUR PATIENTS CAN RELY ON


                *NOAC = non-vitamin K oral anticoagulant

   (S4) INJ. T/30.3/597, 598.   Side effects: Fact.VIII inhibit., dysgeus., naus., inj. site react., al-  rot.oed., concom. meds. act.on haemostas., use with highly activat.
   852902-018: 500 iu/ml, vial +kit, R17 790,08  lerg./anaphylact.react., abnorm.bld press., dizzin, prurit., rash, skin   prothromb. prod.not recomm., elderly, discont.if col. vis.disturbs.exper.
   852899-009: 1 000 iu/ml, vial + kit, R35 538,94  assoc.hypersens. reacts.  Drug interactions: Antagonist.effs.with concom. thrombolyt.&
   Dosage: Reconstit.as per manufact.instructs. Do not exceed inj./  Special precautions: Est.FVIII defic.bef.admin., careful monit.for   poss.reduc.effic.of both, potent. thrombus format.poss.incr.with
   infus.rate of 2 units/kg bm/min. Indiv.  FVIII antibodies, pt.to be made aware of S&S of poss.hypersens.&   concom.oestrog., cerebr.vasosp./ischaem.& poss.bld.flow reduct.
   Guideline dos: 50-100 U/kg bm not exceed. 200 U/kg bm dly.  anaphylact. reacts., long term investigat.of carcinogen.potent. in   with concom.chlorpromazine, concom.high.activ. prothrombin prod.
   Spontan.min.to mod bleed: 50-75 U/kg body weight 12 hrly.until   anim.not perform., no anim.reproduct.stud conduct. theref.potent.
   signs of clinic.improvem.    foet.harm.or whether reproduct. capac.affect.not known, use only   NOVOSEVEN, Novo Nordisk [P/S]
                                                              Activat.recombinant coagulat.factor VIIa (eptacog alfa) produc.
   Maj.musc & soft tiss.haemorrh: 100 U/kg bm 12 hrly.  dur. pregn. & lactat.if clearly indicat. cathet.-relat. infects. with centr.
   Mucous membr.bleed: 50 U/kg bm 6hrly interv.und.careful monit.  ven.access devices but not assoc. with product itself.  in BHK cells.
                                                              Indications: Haemophil.with inhibitors to coagulat. fact.VIII & IX in
   incr.dos to 100 U/kg bm if haemorrh.does not stop not exceed.max.  Interactions: Analges.imp.platel.funct.incr.bleed. tendenc.theref.  life/limb threaten. bleeds/requir.surg. & in home treatm.for early in-
   dly dos.of 200 U/kg bm.      should not be given.          tervent. treat.mild to mod.bleed.episod., bleed. episod. treatm./pre-
   Other sev.haemorrh: 100 U/kg bm 12 hrly.not exceed.max.dly.dos.,   KONAKION, Roche [P/S]  vent.of bleed.in pts.with congenit. fact.VII defic.undergo.surg./invas.
   in indiv.cases admin. 6 hrly. until clinic.improvem.       proced., treatm.of bleed.episod.& prevent.of bleed. in pts.undergo.
   Surg: 50-100 U/kg bm 6 hrly.not exceed.max.dly dos.  Phytomenadione (synthetic Vit.K1)  surg./invas.proced.with Glanzmann’s thrombasthen.with antibod.to
                                Indications: Prophylax.& treatm.of haemorrh.dis. in newborn.
   Prophylax: refer.to manufact.prod.lit.  (S3) MM PAED.AMPS, [P/S] 29/22/0492.   GP IIb-IIIa &/HLA & with past/ pres.refractorin.to platel. transfus.,
   Contra-indications:M/I., coron.art.dis., ac. thrombos./embol.except   866539-018: 2 mg/0,2 ml, 5 amps + 5 dispens., R118,64  bleed.episod.treatm./bleed.prevent.in pts. with acquir.haemophil.
   in life threat.bleed., dissemin.intravasc.coagul.where no respons.to   Dosage: Admin.cont.of amp.into babies mouth.  undergo.surg./invas. proced.
   appropr.coagulat.fact.conc.can be expect.                  (S4) POWD. FOR INJ, 44/8.1/0550, 0551, 0552
   Side-effects: Allerg./anaphylact.reacts., MI aft. high dos./prolong.  Prophylax: Healthy neonates: 2 mg orally at birth, follow.by 2 mg   717176-001: 1 mg vial + 1,1 ml solv.in pre-fill.syr., R11 974,82
                                4-7 days later. A sngl.1 mg dos.admin.I.M.recomm.in childr.not as-
   use &/ in pres.of predispos.risk fact., thromboembol.events with high   sur.of receiv. 2  oral dos/breast-fed childr.not assured of 3  dos.   717182-001: 2 mg vial + 2,1 ml solv. in pre-fill.syr, R23 949,64
                                       nd
                                                          rd
   dos.or in pts.with thrombos.risk fact.  Breast-fed babies: In addit.to above recomm. admin.2 mg orally at   717183-001: 5 mg vial + 5,2 ml solv. in pre-fill.syr, R59,874,12
   Special precautions: Platel.count if respons. inadeq., 6 hrly interv.  mnth.interv.until end of breast-feed.period. Neonates at spec.risk:   Dosage: IV bolus inj.only. Not to be mix.with infus. sol./giv.as infus.
   betw.dos.of another antifibrinolyt.  1 mg IM/IV at birth/soon thereaft.if oral route not suit. Do not exceed   Clinic.results observ.aft. admin.dos: 3-6 KIU (60-120 µg)/kg bm giv.
   Warnings: Concom.use of antifibrinolyt.epsilon aminocaproic acid.  0,4 mg/kg (i.e. 0,04 ml/kg) in prem.infts.weight.less than 2,5 kg. Size   at interv.of 2 hrs or more accord.to bleed.type & eff.obtain. in treatm.
   HAEMOSOLVATE FACTOR VIII, NBI [P/S]  & freq.of furth.dos.depend.on coagulat.status.  of life-& limb-threat.bleeds & in connect.with surg.
   Lyophilis.conc.with a high specific.factor VIII & von Willebrand fac-  Therapy: Init.1 mg I.V.,with furth.dos.as reqd. depend. on clinic.  Haemophil. A or B with inhibitors: Ser.bleed. episod: Dos.var.
   tor prepar.from pooled fresh human plasma., test.& found non-react.  pic.& coagulat.status.  accord.to type & haemorrh.sev. Init. dos.of 4,5 KIU (90 µg)/kg bm
   to HBsAg & antibodies to HCV, HIV-1 & HIV-2 virus. The manufact.   Side effects: Anaphylact.reacts.aft. parenter. use, loc.reacts.  recomm. Init.dos. freq. every 2 nd  hr until clinic.improvem.observ. Dos.
   method incl.process of solv.deterg. treatm. develop.to inactivat.  Special precautions: Parenter.admin.incr. risk of kernicterus in   interv. may be incr.to 3 hrs for 1-2 days. Thereaft. may be incr.success.
   envelop.virus. Efficacy of process has been test.against hepatit.   prem.infts.weigh. &lt;2,5 kg, ensure amps. content clear.  to every 4, 6, 8 or 12 hrs.for as long as treatm.indic. Maj.bleed.episod.
   B, hepatit.C & HIV           Drug interactions: Eff.of coumarin-type anticoags. antagon.  may be treat. for 2-3 wks but extend.if clinic.need.
   Indications: Haemophilia A, acquir./congenit. factor VIII defic.with   (S3) MM AMPS, [P/S] H2250  Surg./invas.proced: Init.dos: 4,5 KIU (90 µg )/kg bm should be giv.
   low levels of factor VIII inhibit, von Willebrand dis.with fact.VIII defic.  826219-004: 10 mg/1 ml, 10 amps, R279,40  immed.bef.proced. Dos.repeat. aft. 2 hrs & then 2-3 hr interv.for first
   (S4) LYOPHIL.POWD.FOR IV INJ 31/30.3/392, Y/30.3/292.  Indications: Haemorrh./threaten.haemorrh. assoc.with vit.K defic.  24-48 hrs depend. on surg.& pt.clinic.status. In maj.surg.dos. should
   841560-005: 300 IU, 1x300 IU vial+dil., R1 135,22  of coagulat.fact. II, VII, IX, &X(10)  be contin.at 2-4 hr interv.for 6-7 days. Dos. interv.may then be incr.
   800759-028: 500 IU, 1x500 IU vial+dil., R1 785,80  Dosage: Amps for IV.inject.or oral use.  to 6-8 hrs for anoth.2 wks. Pts.undergo.surg.may be treat.for up to
   813648-009: 1000 IU, 2x500 IU vials+dil., R3 571,60  Sev./life-threat.haemorrh. e.g. dur.anticoag. ther: Withdr.cou-  2-3 wks until. heal.occur.
   For furth.details refer to manufact.product lit. or Tel. (011) 787-6710.  marin anticoag.and admin. 5-10 mg IV inject.slowly (over at least 30   Fact.IX inhib./acquir.antibod.to Fact.VIII: Exper. in minor surg.only.
                                sec.) with fresh frozen plasma or prothrombin complex concentrate.   Mild to mod.bleed. episod.incl.home treatm: Early interv. in
   HAEMOSOLVEX FACTOR IX, NBI [P/S]  Dose can be repeat.as need.  mild to mod.joint/musc./ mucocutan.bleeds: Recomm.dos.regi-
   Lyophilis.conc.of coag.factors II (prothrombin), VII (proconvertin), IX   Refer to product lit.for specif.IV/oral dos.recomm. in pts.with asymp-  mens: 1-3 inj.of 90 µg (4,5 KIU)/kg bm admin.at 3 hrly interv.with an
   (Christmas factor) & X (Stuart-Prower factor) deriv.from pooled fresh   tom.high INR with/-out mild haemorrh., or maj.life-threat.bleed. Dos.  addit.dos.of 90 µg/kg bm admin.if requir. OR Sngl.inj. of 270 µg/kg
   human plasma., test.& found non-react.to HBs Ag & antibodies to   in elderly should be at low.end of recom.ranges.  bm. Home treatm. durat. not to exceed 24 hrs.
   HCV, HIV-1 & HIV-2 viruses. Manufactur.meth.incl.process of solv.  Oral use: Admin.solut.direct.into pts.mouth with syring.aft. re-  Childr: Gen.differentiat.betw.adult & childr. dos. not warrant.although
   deterg. treatm.develop.to inactiv.lipid-envelop.viruses, efficacy of   mov.needle.  childr.have fast.clear. theref. high.dos.of rFVIIa may be need.in childr.
   which has been test.against hepatit.B, C & HIV  Contraindications: MM amps: Safety in pregn. & lactat.not est.  to achieve similar plasma conc.as in adults.
   Indications: Congenit.(Haemophila B)/ acquir. fact.IX coagulat.  Side effects: Anaphylact.reacts.aft. parenter.use, loc. reacts.  Fact.VII defic: Recomm.15-30 µg/kg bm 4-6 hrly unt. haemostas.
   disords.(sev.bleed.from oral coumar. derivat.anticoags.overdos.)  Special precautions: In life-threat.haemorrh. ther. should be ac-  achiev. Dos.& inj.freq.indiv.
   (S4) LYOPHIL.POWD.FOR IV INJ, W/30.3/191.   compan.by more immed.effect. treatm. e.g.whole bld./bld.clott.  Glanzmann’s thrombasthen: 90 µg (range 80-120 µg)/kg bm bo-
   800767-004: 500 IU,1x10 ml vial+dil. R2 096,99  fact.transfus., elderly, advis.any other consult.physic.of use, ensure   lus inj.at 2 hrly.interv. (1,5-2,5 hrs). At least 3 dos.to be admin.for
   For further details refer to manufacturers product literature   amps.content clear, monit.coagulat. paramet. in sev.imp.liv.funct.,   effect. haemostas. Platelets are first line treatm.if pt.not refractory.
   or Tel. (011) 787-6710.      avoid large dos.if continuat. of anticoag. ther.intend., not an anti-  Acquir.haemophil: Admin.as soon as poss.aft. bleed. episod.start.
   KOGENATE FS, Bayer [P/S]     dote to heparin, in case of recur.thrombos.dur.Konakion treatm. IV   Recomm.init.dos: 90 µg/kg bm by IV bolus. Furth.inj.may be giv.if
                                                              reqd. Treatm. durat.& interv.betw.inj.accord.to sever.of haemorrh./
                                heparin admin.is recom.
   Recombin.antihaemophilic Factor VIII (octocog alfa)  Drug interactions: Eff.of coumarin-type anticoags. antagon., an-  invas.proced./surg. Init.dos.interv.2-3 hrs. May be incr.success.to
   Indications: Treatm.& prophylax.of bleed.in prev. treat.& un-  ticonvuls.poss.imp.act.  4,6,8, 12 hrly for as long as treatm.need.once heamostas.achiev.
   treat.pts.with congenit. Factor VIII defic. (Haemophilia A), pts.with   Contraindications: Known mouse/hamster or bovine prot.hypers-
   Factor VIII inhibit. (neutralis. antibod.)who contin.to respond. (ie.  MORWAK, Dr Reddy’s [P/S]  ens., safety in pregn.& lactat. not est., rare heredit.fruct.intol.probl.,
   achieve. haemostas.)         Tranexamic acid.              gluc. malabsorpt./sucrose-isomalt.insuff.
   (S4) LYOPHILIS.POWD., 41/8.1/1086, 1087, 1088  Indications: Short-term use for haemorrh./ haemorrh risk in incr.  Side effects: Uncomm: Ven.thromboembol. events incl. DVT/
   711415-001: 250 IU, 1x10 ml vial & dil., R1 764,97  fibrinolys./fibrinogenolys.in hyphaema/pts.with est.coagulopathies   thrombos.at IV site/pulm.embol./ thromboembol. events of liv.incl.
   711416-001: 500 IU, 1x10 ml vial & dil., R3 530,09  undergo. min.surg./dent.extract.in haemophil./heredit. angioneu-  portal vein thrombos./ ren.vein thrombos./thrombophlebit./ super-
   711417-001: 1 000 IU, 1x10 ml vial & dil., R7 060,29  rot. oed./menorrhag.  fic. thrombophlebit./intest ischaem., rash, prurit., urticar, decr.ther.
   Dosage: Suit.for paed.pts.of all ages incl. neonates/ infts, childr.&   (S4) TABS, 41/8.1/0742  respon., pyrex.. Rare: Disseminat. intravasc.coagulat., elev. D-dimer,
   adolesc. Admin. reconstit. prod. within 3 hrs with admin set prov.  719414-001: 500 mg, 20, R133,23  decr. AT-III, coagulopathy, hypersens., naus., headache, arterial throm-
   Indiv.dos.accord.to pts.need/severity of defic./ severity of haem-  Dosage: Traumat.hyphaem: 1-1,5 g 8 hrly.x6-7 days.  boembol.events incl.MI/ cerebr. infarct./ cerebr.ischaem./cerebr.ar-
   orrh./pres.of inhibit. & fact.VIII lev. desir. Eval.effectiven.by clinic.  Est.coagulopathy pts.undergo.min.surg: Cerv. conisat: 1-1,5 g   tery occlus/ CVA/ ren.artery thrombos./periph. ischaem./ periph.arter.
   eff. If calcul. dos. fails to attain expect.fact.VIII lev.or if bleed. not   8-12 hrly for 12 days post-op.  thrombos./intest.ischaem., ang. pect., flush., angioed., inj.site reacts.,
   control.consid.pres.of circulat.inhibit. Pres.& lev. of inhibit.to be   Dent.proced: 25 mg/kg 2 hrs pre-op with Factor VIII and Factor IX   incr. alanine aminotransfer./alkaline phosphat./lactate dehydrogen./
   substant.by lab.tests.       then 25 mg/kg 3-4 xdly for 6-8  days post-op.  prothrombin lev., incr.fibrin degradat. prods. Unknown: Anaphylact.
   Adapt rate of admin.to respons.but admin.entire dos. in 5-10 mins.  Heredit.angioneurot.oed: 1-1,5 g 2-3 xdly for some days or con-  react, intracard. Thrombus.
   well tolerat.                tin.in some pts.              Special precautions: Cons.benef./risk dur. breast feed., arter.
   Gen.dos.guidelines to maint.therapeut. plasma lev: Min.  Menorrhag: 2-3 tabs.3-4 xdly giv.aft.heavy bleed. has start.  thromboembol.events risk outside approv.indicats., thrombot.event/
   haemorrh: 10-20 IU/kg. Rep. dos. if evid.of furth.bleed. Mod.to   Contraindications: Thrombo-embol.dis.hist., col. vis. disord.,   dissemin. intravasc.coagulat.(DIC) induct. developm. poss.aft.maj.
   maj.haemorrh: 15-30 IU/kg. Rep one dos.at 12-24 hrs.if need. Maj.   thrombophlebit., imp.liv.funct., subarachn.bleed., safety in pregn.&   surg./in condits.in which tiss. fact.may be express.more extensively
   to life-threat.haemorrh: Init.dos.40-50 IU/ kg. Rep.dos.20-25 IU/kg   lactat.not est.  theref. monit.for untoward activat.of coagulat.syst./ thrombos., con-
   every 8-12 hrs. Maj. surgic. proced: Pre-op dos: 50 IU/kg. Verify   Side effects: GI disords., thrombo-embol.events.  sid.benef.vs.risk in coron.heart./liv. dis./ neonat./pts.at risk of throm-
   ~100% activ.prior to surg. Rep.as necess.aft.6-12 hrs. init.& x10-14   Special precautions: Pass.into breast milk, ren. insuffic., massive   boembol.phenom. /DIC, pt.monit.of early signs & advis.to discont.
   days until heal.complete.    upper urin.tract.haematur.to reduc. ureter.obstruct.risk, when dissem.  ther. immed.in case of allerg./anaphylact.type reacts., sev.bleeds
   Contraindications: Not indicat.for von Willebrand’s dis., mouse/  intravasc. coagulat.is in progr., reg.eye exam.incl.vis.acuity/ slit lamp/  monit.by haemophil.spec. physic., mild to mod.bleed.poss.treat.at
   hamster prot.hypersens.      IOP/vis.fields & LFT advis.dur.longt.ther. in pts. with heredit.angioneu-  home with reg. monit.by haemophil.centre, no clinic.exper. with sngl.
                        S4 Pradaxa ® . 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131. S4 Pradaxa ® . 150 mg. Each capsule contains 150 mg of dabigatran
                        etexilate base (as mesilate salt). Reg. No. 45/8.2/0162. For full prescribing information refer to the professional information approved by the Regulatory Authority.
                        Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100406. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page166.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>&nbsp;&nbsp;&nbsp;<a href="page167.html">167</a>&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>
             </td>
             <td width="35%"><a href="page168.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page168.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
